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Abstract 
Pesticides can exert adverse effects on different target organs via the activation of nuclear 
receptor pathways. Hepatotoxic effects of the widely used triazole fungicide propiconazole 
(Pi) are generally attributed to the activation of the ligand-activated transcription factor 
constitutive androstane receptor (CAR) or the pregnane X receptor (PXR). We now 
investigated the effects of Pi on the ligand-activated transcription factor aryl hydrocarbon 
receptor AHR. Therefore, the effects of Pi on AHR-dependent reporter gene transactivation, 
AHR target gene mRNA and protein expression as well as enzyme activities were examined 
in HepG2 or HepaRG human hepatoma cells using dual luciferase assays, RT-PCR, mass 
spectrometry or the ethoxyresorufin-O-deethylase assay, respectively. Additionally mRNA 
expression and enzyme activity was analyzed in rat liver ex vivo. Furthermore, AHR target 
gene expression was measured in AHR-, CAR-, and PXR- knockout HepaRG cells. 
Subsequently, we investigated combination effects of Pi and the model AHR ligand 
benzo[b]fluoranthene (BbF) in vitro. 
Our results show that Pi activates the AHR in reporter gene assays in human HepG2 cells. 
This dose-dependent activation of the AHR was subsequently confirmed by real-time RT-
PCR analyses of the model AHR target genes CYP1A1 and CYP1A2 in human HepaRG 
cells and in livers of rats treated with Pi for 28 days via the diet. In addition, results of 
CYP1A1 protein level quantification showed Pi-dependent induction of the enzyme. CYP1A1 
enzyme activity measurements demonstrate that higher concentrations of Pi significantly 
induce CYP1A1-dependent reactions in human HepaRG cells and in rat liver. Gene 
expression analysis in AHR-knockout HepaRG cells showed no induction of CYP1A1 and 
CYP1A2, whereas gene expression in CAR-, and PXR-knockout cells was induced. 
Furthermore, mixture effects of Pi and BbF were observed in human cell lines. Modeling of 
dose-response curves revealed that these cellular effects can be explained by concentration 
additivity. In conclusion, our results demonstrate that the triazole Pi is an activator of AHR.  
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1. Introduction 
For assessment of mixture effects, mode of action analysis is critical because the nature of a 
combination effect (i.e. whether similar or dissimilar action occurs) depends on the molecular 
interactions of substances with receptors (Kortenkamp et al., 2009). Substances affecting the 
same target tissue by the same mechanism (e.g. the liver by AHR or PXR activation) are 
generally assumed to behave in a concentration-additive manner, while diverging target 
organs and mechanisms would lead to independent action. 
Many azole compounds show a hepatotoxic potential in standard toxicity tests.  
Propiconazole (Pi), a triazole fungicide, for example causes hepatocellular hypertrophy and 
vacuolization as well as hepatocellular tumors in long-term rodent bioassays (EFSA, 2010). 
The constitutive androstane receptor (CAR) plays a crucial role in liver toxicity of several 
azoles, as evidenced by gene expression profiles (Currie et al., 2014; Goetz and Dix, 2009; 
Heise et al., 2017; Heise et al., 2015) as well as by experiments in knockout mice (Peffer et 
al., 2007) or humanised mice (Marx-Stoelting et al., 2017). An additionally key mediator of 
azole-mediated hepatotoxicity is the pregnane X receptor (PXR) (Goetz and Dix, 2009; 
Hester and Nesnow, 2008). More specifically, it has been suggested that these two receptors 
are important for the effects also of Pi on the target organ liver (Currie et al., 2014; Hester 
and Nesnow, 2008). In contrast, the aryl hydrocarbon receptor (AHR) has not yet been 
described as a key receptor in Pi-mediated liver toxicity in human. Hints on involvement of 
the AHR in Pi mediated toxicity have been found in other studies involving mice, rats or 
rainbow trouts (Ghisari et al., 2015; Li et al., 2013; Sun et al., 2005). Other azole fungicides 
like imazalil, which have been tested for their ability to activate human AHR, were found not 
to be AHR activators but CYP1A1 inducers (Sergent et al., 2009). However, the imidazole 
fungicide prochloraz has been proposed to exert its effects by activating AHR (Halwachs et 
al., 2013; Marx-Stoelting et al., 2017; Rieke et al., 2014) while an involvement of CAR in 
prochloraz-dependent liver toxicity has also been proposed (Goettel et al., 2015). Since 
imidazoles and azoles are structurally related and an AHR activation has been shown in 
other species, the hypothesis that at least some azoles may also interfere with the human 
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AHR seems plausible and worth of investigation, considering also potential implications for 
mixture toxicity. 
Benzo[b]fluoranthene (BbF) is a polycyclic aromatic hydrocarbon (PAH) found as 
contaminant in food, e.g. in roasted coffee (Jimenez et al., 2014). Like many other PAHs BbF 
exerts at least parts of its toxicity via the AHR (Andrysik et al., 2007). Interestingly, for some 
AHR ligands including PAHs like benzo[a]pyrene (BaP), species differences have been 
observed in terms that these substances show a higher affinity to murine AHR (mAHR) as 
compared to its human counterpart (Flaveny et al., 2009). This emphasizes the need to 
investigate rodent liver toxicants, known to activate AHR, also for their ability to transactivate 
the human AHR. 
The aim of this work was to analyze AHR activation by Pi in human cell lines and in rats. 
Furthermore, mixture effects of Pi and the model AHR ligand BbF on this receptor were 
investigated. 
 
2. Materials and methods 
2.1 Test substances 
Propiconazole (CAS # 60207-90-1; Batch # CGA64250B; purity 96.10%) was acquired in 
technical quality from Syngenta AG (Basel, Switzerland) and benzo[b]fluoranthene (CAS # 
205-99-2; purity 98.00%) from Sigma-Aldrich (Taufkirchen, Germany). For receptor 
transactivation assays, propiconazole in analytical quality from LGC Standards (Wesel, 
Germany) (CAS # 60207-90-1; Batch # G144536; purity 99.00%) was used. For dilution of 
the test substances, DMSO (dimethylsulfoxide) was used, resulting in a final DMSO 
concentration of 0.2% in the treatment medium. For mixture experiments concentrations of 
the test substances were halved (10 µM A+B corresponds to 5 µM A + 5 µM B). 
 
2.2 Cultivation of cells 
The human hepatocellular carcinoma cells HepaRG were acquired from Biopredic 
International (Saint Grégoire, France) and cultured as previously described (Gripon et al., 
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2002). For a period of two weeks the HepaRG cells were incubated in the proliferation 
medium which consists of Williams E medium (Pan-Biotech GmbH, Aidenbach, Germany), 
10% fetal calf serum (FCS; Pan-Biotech GmbH), 100 U/ml penicillin, 100 µg/mL 
streptomycin, 0.05% human insulin (PAA Laboratories GmbH, Pasching, Austria) and 50 µM 
hydrocortisone-hemisuccinate (Sigma-Aldrich). For differentiation of the cells they were 
incubated for further two weeks in differentiation medium, which encloses the proliferation 
medium and 1.7% DMSO. Differentiated cells were treated with test substances in phenol 
red-free Williams E medium (Pan-Biotech GmbH) including the same supplements as the 
differentiation medium, but only 2% FCS. 
The PXR, AHR, and CAR knockout HepaRG cells were purchased from Sigma-Aldrich. The 
cultivation was done according to the manufacturers’ protocol. In brief, cells were thawed in 
recovery medium (Sigma-Aldrich) and cultivated in recovery medium for two days. 
Afterwards, cells were cultured for a period of two weeks in maintenance medium (Sigma-
Aldrich). It follows one day in pre-induction-medium (Sigma-Aldrich) before the cells were 
treated in serum-free-induction medium (Sigma-Aldrich). 
The incubation of HepG2 cells (ECACC, Porton Down, UK) was performed in DMEM 
medium (Pan-Biotech GmbH) which included 10% FCS. When the cells had reached a 
confluency of about 80%, cells were passaged. Treatment with the test substances was 
performed in phenol red-free DMEM medium (Pan-Biotech GmbH) supplemented with 10% 
FCS (Pan-Biotech GmbH) for 24 hours. Incubation of both cell lines was done at 37°C and 
5% CO2 in a humidified atmosphere in a Binder cell culture incubator. 
 
2.3 Testing of cell viability 
For analysis of cell viability, we used the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) reduction assay according to standard protocols (Braeuning et 
al., 2012). The detergent Triton X-100 (0.01%) was used as positive control. 
 
2.4 Animal experiment. 
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The animal experiment was conducted as previously described (Schmidt et al 2016). In brief, 
5-6 week old male Wistar rats were treated with propiconazole via rodent standard diet for 28 
days at a dose level of 2.4 ppm, 240 ppm or 2400ppm yielding 181 mg/kg bw/d. Animals 
were deeply anaesthetized with Sevofluran (Abbot, Germany), finally sacrificed by 95% CO2 / 
5% O2 and livers were isolated.  Directly after isolation, livers were partially frozen on dry ice 
for subsequent molecular analysis. Additionally, standard pathology and histopathology were 
performed according to standard principles of the Society for Toxicopathology (STP 2010) as 
previously reported (Schmidt et al 2016). 
 
2.5 Molecular modelling 
The human AHR primary structure was downloaded from the UniProt Protein 
Knowledgebase database [entry: P35869]. After a protein Blast search of the Protein Data 
Bank database for a human AHR homolog, the crystal structure of human hypoxia-inducible 
factor α (HIF-2α) ligand binding domain (LBD) (Erbel et al., 2003) in its apo-form was set as a 
template. An alignment produced by the Clustal Omega software was manually checked. 
Comparative model building was carried out by the MOE Homology Model program of the 
Protein module with default settings. The quality of the final model was carefully checked 
with the MOE Protein Geometry program. The binding site of the AHR was identified through 
the MOE Site Finder program, which uses a geometric approach to list putative binding sites 
in a protein, starting from its three-dimensional structure. Pi and the reference compound 
2,3,7,8-tetrachlorodibenzo[p]dioxin (TCDD) were downloaded from the PubChem database. 
Each structure was converted into a three-dimensional structure, and energy minimized, with 
the MOE Energy Minimize program down to a RMS gradient of 0.05 kcal/mol/Å2. 
Stereochemistry of each structure was carefully checked. Molecular docking was carried out 
through the MOE Dock program. The Triangle Matcher placement algorithm was selected 
and the London dG empirical scoring function was used for sorting the poses. The 30 top-
scoring poses were refined through molecular mechanics, considering the AHR as a rigid 
body, and the refined complexes were scored through the GBVI/WSA dG empirical scoring 
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function, selecting the five top-scoring poses and estimating their binding free energy (ΔG) to 
the ligand binding domain of AHR. 
 
2.6 Reporter gene assays 
The dual luciferase reporter gene assays were performed using HepG2 cells in 96-well 
plates. For transiently transfection of the cells, TransIT-LT1 (Mirus Bio LLC, Madison; WI, 
USA) was used. For each assay, the cells were transfected with two plasmids (see table 1). 
A detailed description of the generation and the features of the luciferase reporter constructs 
used in this study is available elsewhere (Schreiber et al., 2006; Schulthess et al., 2015). In 
brief, a pT81Luc-based firefly luciferase reporter driven by a 1.2 kbp fragment of the wildtype 
human CYP1A1 promoter including four functional AHR binding sites was used. In addition, 
a mutant version of the promoter lacking these AHR-responsive sites (-CDEF) came into 
operation. Third, a pT81Luc-based artificial promoter construct consisting of three AHR 
binding sites (3xDRE) was used. For all three assays, cells were co-transfected with a 
second plasmid, which constitutively expresses Renilla luciferase and served as internal 
control. After transfection, treatment and lysis of the cells (100 mM potassium phosphate with 
0.2% (v/v) Triton X-100, pH 7.8), luminescence was measured using a plate reader (Infinite 
M200PRO, Tecan, Männedorf, Switzerland) according to the Dual Luciferase Assay protocol 
provided by the supplier (Promega, Madison, WI, USA). 
 
Table 1: Plasmids used for dual luciferase reporter gene assays in HepG2 cells. 
Luciferase 
assay 
Plasmid 
Time of 
incubation 
Positive control 
hCYP1A1-
promoter 
pT81Luc-hCYP1A1 
48 h 10 µM BbF 
pcDNA3-RLuc 
hCYP1A1 
(-CDEF)-
promoter 
pT81Luc-hCYP1A1-CDEF 
48 h 10 µM BbF 
pcDNA3-RLuc 
3xDRE 
pT81Luc-3xDRE 
24 h 10 µM BbF 
pcDNA3-RLuc 
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2.7 Gene expression analysis 
HepaRG cells and HepaRG knockout cells were treated for 24 hours in 6 well plates with the 
test substances. RNA from cells as well as from rat liver tissues frozen in nitrogen was 
isolated using peqGOLD TriFast (peqlab, Erlangen, Germany) or TRIzol reagent (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturers’ protocol. Quality and quantity of the 
isolated RNA were controlled with a Nanodrop spectrophotometer (NanoDrop 2000, Thermo 
Fisher Scientific, Waltham, MA, USA). If necessary, RNA was further purified using a RNA 
purification kit (Qiagen, Hilden, Germany).The human microarray Agilent Expression Profiling 
Service (incl. 8x60K Array) was performed by ATLAS Biolabs GmbH. Obtained results were 
further analyzed using the bioinformatic analysis and search tool IPA (Ingenuity Pathway 
Analysis) from QIAGEN. Therefore, the IPA “Tox Analysis” tool was used. All analyses were 
performed with the standard settings, where no filtering was applied and direct as well as 
indirect relationships were considered (date of the search: 2017/11/10). Real-time RT-PCR 
was performed as described previously (Heise et al., 2015). In brief, reverse transcription of 
1 µg of RNA (HepaRG cells) or 2 µg RNA (rat livers) was conducted using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt, Germany). Quantitative 
real-time PCR was performed of 40 ng cDNA on an ABI 7900HT instrument (Applied 
Biosystems) using Maxima SYBR Green/ROX qPCR Mastermix (Thermo Fisher Scientific) 
and primers (0.25 µM, synthesized at Eurofins Genomics, see Table 2).  
  
Table 2: Sequences of primers used for RT-PCR analysis. 
gene name forward primer reverse primer 
hGAPDH CCACTCCTCCACCTTTGAC ACCCTGTTGCTGTAGCCA 
hACTB ACCGAGCGCGGCTACAG CTTAATGTCACGCACGATTTCC 
hCYP1A1 TGTCAGTGGCCAACGTCATT AGGGTTAGGCAGGTAGCGAA 
hCYP1A2 TGCAAGACAAGCTGGTGTCTA 
 
TCTCATGCGCTCACAGAACT 
 
rGapdh CCGTGGGGCAGCCCAGAAC GCCCCAGCATCAAAGGTGGAGGA 
rActb AGGGAAATCGTGCGTGAC CGCTCATTGCCGATAGTG 
rCyp1a1 TTCACCATCCCCCACAGCACCATA CAGGCCGGAACTCGTTTGGATCAC 
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rCyp1a2 CGGTGATTGGCAGAGATCGG GTCCCTCGTTGTGCTGTGG 
 
2.8 CYP protein quantification 
HepaRG cells were treated with the test substance Pi for 24 hours in 6-well plates. After two 
washing steps with ice-cold PBS-buffer, the cells were incubated for 1 hour at 4 °C with lysis 
buffer under shaking (Zahn et al., 2017). Afterwards, each sample was prepared and 
measured as described previously (Marx-Stoelting et al., 2017; Wegler et al., 2017). In brief, 
a proteolysis was performed and multi-specific antibodies recognizing short C-terminal 
sequences of proteotypic peptide fragments were mixed with isotopically labeled peptides. 
With the help of an automated immunoprecipitation procedure endogenous peptides and 
standards for the proteins were enriched (Weiß et al., 2015). Peptide-antibody-complexes 
were precipitated with magnetic protein G microspheres using a magnetic particle processor. 
Elution was achieved with 1% formic acid and peptides were subsequently desalted by a 
PepMap100 µ-precolumn (0.3 mm I.D. x 5 mm, Thermo Fisher Scientific, Waltham, MA, 
USA) and separated by an Acclaim Rapid Separation LC (RSLC) Column (75 µm I.D. x 
150 mm; Thermo Fisher Scientific, Waltham, MA, USA) on a UltiMate 3000 RSLCnano LC 
system (Thermo Fisher Scientific, Waltham, MA, USA). After that, peptides were quantified 
with a Q Exactive™ Plus (Thermo Fisher Scientific, Waltham, MA, USA) using targeted 
Single-Ion-Monitoring (tSIM). Ion chromatograms were processed with Skyline 3.7.0.11317 
(MacCoss Lab. Department of Genome Sciences, UW, USA). Concentrations were 
calculated by the peak area ratios of isotopically labeled and endogenous peptides on parent 
ion level. The analyte-dependent lower limits of quantification (LLOQ) were determined with 
a dilution series of standard peptides (0.1-0.4 fmol/µg). 
 
2.9 CYP activity assay 
HepaRG cells were treated for 24 hours in 96-well plates with the test substances. 10 µM of 
the substrate 7-ethoxyresorufin was added to each well and incubated for 30 minutes at 
37°C. Liver microsomes were isolated in a 250 mM sucrose buffer (Merck, Darmstadt, 
Germany) by differential centrifugation at a final speed of 100,000g for 1 h. Afterwards, the 
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O-dealkylation of the substrates 7-ethoxyresorufin (EROD) and 7-methoxyresorufin (MROD) 
were measured to detect the enzyme activity of CYP1A1/Cyp1a1 and CYP1A2/Cyp1a2 using 
resorufin as a standard (reagents obtained from Sigma-Aldrich, Basel, Switzerland). The 
assay was performed at 37 °C in a KH2PO4/K2HPO4 buffer at pH 7.4. Fluorescence 
measurements (535 nm/ 590 nm) were conducted on a Tecan Plate Reader (Tecan, Infinite 
M200Pro). 
 
2.10 Statistical analysis 
The statistical analysis was performed using SigmaPlot for Windows software (Version 13.0, 
Systat Software Inc. 2008). The Shapiro-Wilks and Brown-Forsythe tests were used to 
analyze the data for normal distribution and for homogeneity of variances. These results 
demonstrated that non-parametric testing is the adequate testing method for the present data 
sets. Therefore the Mann-Whitney rank sum test was executed to compare the solvent 
control to respective treatment groups. Error bars depict the standard deviation and asterisks 
(*) define statistical significance if p ≤ 0.05. For the combination experiments, a statistical 
dose-response modeling was performed. PROAST software (www.proast.nl) was used to 
analyze concentration addition of the combinations, as described previously (Kienhuis et al., 
2015). 
 
3. Results 
3.1 Microarray gene expression data indicate AHR activation by Pi in human cells 
In the course of a study aimed to investigate global transcriptomic responses of human liver 
cells to the fungicidal active substance Pi in vitro, we discovered that CYP1A1 and CYP1A2, 
the most classic target genes of the nuclear receptor AHR, were among the top upregulated 
genes in HepaRG hepatocarcinoma cells (see supplementary Table 1 for the full list of Pi-
regulated genes). Microarray analysis was verified by conventional real-time RT-PCR of 
CYP1A1 and CYP1A2 (see 3.3 below). The literature-based bioinformatic IPA (Ingenuity 
Pathway Analysis) was used to unravel possible further hints for AHR activation by Pi. These 
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analyses revealed that other genes which have been previously linked to AHR activation 
were also altered by Pi (Figure 1A). For most of these genes the direction of regulation was 
in line with previously published data on AHR-dependent activation or inhibition of these 
genes (Figure 1A). As the results from bioinformatic data mining indicated a possible 
involvement of the AHR in Pi-induced effects in human liver cells, further experimentation 
was conducted for verification. 
 
3.2 In silico docking of Pi to the AHR 
In a first step molecular docking simulations were performed to assess in silico whether Pi 
can bind the ligand binding domain of human AHR. A negative DG value of -3.8 kcal/mol was 
predicted (Figure 1B), suggesting that an association between the AHR and Pi is favorable 
from an energetic point of view. TCDD, a reference ligand for AHR, showed a ΔG value of -
5.0 kcal/mol (Figure 1C). This can still be regarded as not a so favorable value, indicating 
that the human AHR ligand binding domain interacts rather weakly with its reference ligand. 
The superposition of TCDD and Pi in the AHR ligand binding site showed a partial overlap of 
the aromatic rings of these two chemicals (Figure 1D). The predicted DG value is suggestive 
but not sufficiently negative to firmly support binding of Pi on AHR, just basing on our in silico 
data. For this reason, AHR activation by the compound was further studied in more detail 
using experimental approaches. 
 
3.3 Pi induces AHR-dependent transcription, target mRNA, protein amount, and enzyme 
activity 
In a next step we therefore analyzed whether Pi would activate AHR-dependent transcription 
using a luciferase reporter system driven by either a 1.2 kbp fragment of the human CYP1A1 
promoter, a similar CYP1A1 promoter-derived luciferase reporter lacking the four functional 
AHR binding sites (“-CDEF”), or an artificial promoter construct consisting of three AHR-
responsive DRE sequences (“3xDRE”). As shown in Figure 2A and 2C, Pi dose-dependently 
induced luciferase reporter activities from the CYP1A1 promoter and 3xDRE constructs in 
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HepG2 human hepatoma cells with statistical significance, whereas no induction was visible 
with the AHR binding site-deficient mutant (-CDEF) reporter (Figure 2B). When compared to 
the positive control, the aromatic hydrocarbon and known AHR inducer BbF, it became 
obvious that Pi showed an onset of reporter gene activation only at substantially higher 
concentrations than needed for BbF to produce a response. Thus, Pi constitutes a 
substantially weaker AHR activator than BbF. Analyses of Pi-induced effects at higher 
concentrations than 40 µM, in order to add information to the right side of the dose-response-
curve, were hampered by cytotoxic effects occurring at these concentrations; please see 
Supplementary Figure 1 for cell viability analyses of Pi in HepG2 (A) and HepaRG (B) cells. 
To exclude that the observed AHR activation was caused by impurities potentially present in 
technical grade Pi the experiments were repeated with analytical grade Pi and the results 
were reproduced (Supplementary Figure 2A and 2B). 
 
Dose-dependent induction of AHR activity was subsequently confirmed by real-time RT-PCR 
analyses of the model AHR target genes CYP1A1 and CYP1A2 in HepaRG cells (Figures 3A 
and 3B). These results well resembled the findings at the reporter gene level. Expression of 
the AHR mRNA itself was not altered (data not shown). In addition, abundance of CYP1A1 
was quantified at the protein level using a mass spectrometry-based approach. Results of 
these analyses showed Pi-dependent induction of CYP1A1 protein (Figure 3C), consistent 
with the findings presented above. To further substantiate our findings we studied CYP1A1-
dependent catalytic activities using the classic EROD (ethoxyresorufin-O-deethylase) assay 
for CYP1A1 activity. Figure 3D demonstrates that Pi was able to significantly induce 
CYP1A1-dependent enzymatic substrate conversion in human HepaRG cells in a dose-
dependent manner. 
Similar effects were observed in rat liver: Cyp1a1 and Cyp1a2 gene expression was 
significantly increased at the top dose level in Pi-treated rats (Figure 4A and 4B). Additionally 
Cyp1a1 and Cyp1a2 enzyme activities were significantly increased in a dose-dependent 
manner (Figure 4C and 4D). 
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3.4 Effects of Pi in AHR KO, PXR KO and CAR KO HepaRG cells  
Three HepaRG cell lines deficient of either AHR, PXR or CAR were treated with Pi and 
CYP1A1 and CYP1A2 gene expression was analyzed to investigate if Pi-induced gene 
expression was mediated by either of the three receptors. Involvement of CAR and PXR in 
Pi-dependent gene regulation has been reported previously. As shown in Figure 5A and 5B, 
CYP1A1 and CYP1A2 upregulation was completely blocked in AHR KO cells. Comparable 
results were seen when using HepG2 cells treated with a pharmacological inhibitor of the 
AHR and a Cyp1A1 promoter driven reporter (5C). In contrast CYP1A1 and CYP1A2 gene 
expression was upregulated in a concentration dependent manner in both PXR KO (5D and 
5E) cells as well as CAR KO (5F and 5G) cells, similar to wildtype cells. These results 
indicate that knockout of PXR and CAR has no remarkable influence on the upregulation of 
these genes by Pi, whereas presence of the AHR is crucial.  
 
3.5 Combination effects of Pi and the model AHR ligand BbF 
According to a previous publication linking Pi and rodent AHR, Pi alone activates the rodent 
AHR but might inhibit the response to model AHR ligands (Ghisari et al., 2015). We therefore 
exposed human hepatic cells in vitro to mixtures of Pi and BbF, a model AHR activator 
routinely used in our laboratory. Figure 6A demonstrates that no inhibition of BbF-mediated 
induction of AHR-dependent 3xDRE reporter activities was observed when applied in 
combination with Pi. Instead, data were consistent with the assumption of concentration 
addition (Supplementary Figure 3A). When analyzing mRNA induction of CYP1A1 (6B) and 
CYP1A2 (6C) in response to Pi and BbF mixtures, concentration addition was observed 
(Supplementary Figure 3B and 3C). The analysis of respective enzyme activity of CYP1A1 in 
the EROD-Assay showed similar results (Figure 6D and Supplementary Figure 3D). 
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4. Discussion 
Data presented in this paper clearly demonstrate that Pi is an activator of the human AHR, 
as consistently shown by analyses at the reporter gene, mRNA expression, protein 
abundance, and enzyme activity levels in HepG2, HepaRG, or HepaRG variants bearing 
knockouts of individual nuclear receptors. Furthermore, investigation of gene expression and 
enzyme activity in rat livers showed induction of the AHR targets Cyp1a1 and Cyp1a2 in 
vivo.  
So far, only few previous publications have established indirect links between Pi and the 
AHR. (Sun et al., 2005) administered Pi to rats and observed an induction of Cyp1a2 gene 
expression and resulting enzyme activity without analyzing receptor binding and 
transactivation. (Li et al., 2013) measured induced hepatic EROD activity in juvenile rainbow 
trout exposed to Pi when compared to the control group. They suggest that Pi had toxic 
effects in the fish through binding to the aryl hydrocarbon receptor (AHR) without analyzing 
receptor binding or transactivation. In human intestinal cells, an increase of CYP1A1 activity 
after treatment with imazalil and other conazoles like Pi has been published (Sergent et al., 
2009). However, imazalil was shown not to bind AHR while Pi was not investigated. (Ghisari 
et al., 2015) have screened various compounds for activation of rodent AHR using a murine 
cell line stably transfected with an AHR-responsive reporter construct and reported a 
concentration of 10 µM Pi as the lowest dose to exert an effect. Given the differences in 
incubation conditions and reporter system used, these results appear well in line with our 
present findings, indicating that Pi is a weak agonist of human as well as rodent AHR. 
Altogether, the present data on AHR activation by Pi go far beyond what has been published 
previously by (Ghisari et al., 2015) who followed a screening approach in a rodent cell 
system rather than systematically characterizing the properties of an individual compound in 
human hepatic cells, as was the focus of our study.  
While the AHR has initially been believed to become activated rather specifically by 
polycyclic aromatic compounds, such as (halogenated) polycyclic aromatic hydrocarbons, 
dioxins, and certain polyhalogenated biphenyls, more recent data have revealed that 
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numerous other compounds not exactly fitting into this class of molecules are capable of 
activating the receptor. For example, certain experimentally used ATP-competitive kinase 
inhibitors such as U0126 and SB216763 (Andrieux et al., 2004; Braeuning and Buchmann, 
2009) phytochemicals such as isoflavones (Van der Heiden et al., 2009) and also 
endogenous metabolites such as kynurenine (Opitz et al., 2011) are activators of the AHR, 
which, however, in most cases do not share the potency or the long biological half-life of the 
model activator TCDD. The present observations thus fit well into this picture of a somewhat 
promiscuous receptor. Since species-specific differences with regard to the agonistic 
properties of foreign compounds at different nuclear receptors have been noted it is 
important to show activation of the human receptor to draw a conclusion to the relevance for 
humans. A very prominent example of species-species differences is the receptor CAR, 
where CITCO is considered a specific agonist of human CAR, whereas TCPOBOP activates 
the receptor in mice but not in humans (Tzameli et al., 2000). However, such observations 
are not limited to CAR: the best-studied AHR activators, e.g. TCDD or polycyclic aromatic 
hydrocarbons, generally activate both, the AHR of humans and of rodents. They do so, 
however, with sometimes remarkable quantitative differences: for example, binding of TCDD 
to the human AHR has been reported to occur with approximately 10-fold lower affinity than 
for the most common AHR variants expressed in the mouse (Ema et al., 1994). Similar 
differences have been observed for other AHR ligands and also for species other than only 
humans and rodents, as for example documented in detail in (Denison et al., 2011; Flaveny 
et al., 2009). Species differences have also been described with respect to AHR antagonists, 
for example SR1 which acts as an antagonist of human but not rat AHR (Boitano et al., 
2010). These observations underline the importance of conducting studies with human cells 
in order to assess possible toxicological consequences of nuclear receptor activation by 
foreign compounds in humans. It has to be noted that comparative analyses of the response 
of the AHRs from different species are not routinely performed, as can be taken from the lack 
of such data in many publications identifying novel AHR agonists.  
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In the paper by (Ghisari et al., 2015) it is mentioned that Pi attenuated the AHR-inducing 
effects of the model AHR activator TCDD in the murine cell system used there. As, however, 
no exact values are given, one cannot judge the strength and/or significance of this 
observation. Due to the fact that toxicological effects of mixtures have become an 
increasingly important topic during the past years, we investigated how Pi and the model 
AHR ligand BbF jointly influence AHR activity in human cells. Our results do not support the 
abovementioned finding by (Ghisari et al., 2015) according to which one would expect AHR 
activation by a model ligand to be diminished by Pi. Instead, our findings are in line with a 
model of concentration addition. The validity of this model for AHR activators constitutes the 
basis of current assessment of classic AHR activators: for these substances, additivity is 
assumed and concentrations of individual substances, multiplied with their equivalence factor 
(a measure for their potency relative to TCDD), can be added in order to predict a mixture 
effect. Our present data suggest that this type of additivity is also valid for mixtures of Pi with 
other AHR activators. 
Pi belongs to a large family of frequently used fungicidal active substances, the triazole 
fungicides. These compounds are closely related with respect to their molecular structure. 
The finding that Pi is an AHR activator thus triggers the question whether this holds also true 
for other members from this chemical class. We have investigated two related substances, 
namely cyproconazole and tebuconazole. We couldn’t observe any AHR activation after 
treatment with cyproconazole or tebuconazole when tested with the sensitive endpoint of 
luciferase reporter analysis up to the highest possible non-cytotoxic concentrations (own 
unpublished data). Instead, cyproconazole acts as an activator of human and rodent PXR 
and also rodent but not human CAR (Marx-Stoelting et al., 2017), whereas tebuconazole 
also activates PXR but is an antagonist of CAR (Knebel et al., 2018). Together these 
observations demonstrate that despite evident similarities at the level of chemical structure, 
the molecular targets of these substances differ considerably. This might have implications 
for risk assessment, where adverse effects in the liver following activation of certain nuclear 
receptors by xenobiotics is not considered relevant for humans, as in case of the peroxisome 
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proliferator-activated receptor (PPAR) alpha (Corton et al., 2014), or is subject of a 
controversial scientific debate, as in case of CAR activation (Braeuning et al., 2014; 
Braeuning et al., 2016; Braeuning et al., 2015; Elcombe et al., 2014; Yamada et al., 2014). 
By contrast, the most potent and specific xenobiotic inducer of the AHR, TCDD, has been 
classified as carcinogenic to humans by the International Agency for the Research on 
Cancer (IARC) and others (Baan et al., 2009). Different triazole fungicides appear to activate 
different sets of nuclear receptors and show variable potencies at the individual receptors. 
Adverse liver effects in experimental animals exposed to such substances might be 
contributed to by a single receptor or by a combination of multiple receptors simultaneously 
activated by a certain compound. Based on classic histopathology it appears almost 
impossible to deduce a specific molecular mechanism from observations at the tissue level. 
Many adverse outcome pathways (AOP) describing adversity as a sequence of molecular 
events triggering an adverse outcome at the organ level contain multiple molecular initiating 
events which later converge at the cellular level (www.aopwiki.org). For example, the AOP 
for liver steatosis comprises almost all important nuclear xeno-sensing receptors, such as 
AHR, CAR, PXR, and PPAR. Proof of activation of a certain receptor by a chemical does not 
always allow drawing conclusions on the prevailing molecular mechanisms, since a 
compound, e.g. a triazole, might be able to simultaneously act on a whole set of receptors. 
Thus, when judging on the human relevance of experimental data, not only possible species 
differences with respect to ligand-receptor interaction should be taken into account, but it 
should also be regarded as important to keep in mind that mechanistic toxicological 
argumentation for or against human relevance of a certain adverse effect should involve the 
different possible modes of action which are driven by individual nuclear receptors but lead to 
a similar adverse outcome. 
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Figures 
Figure 1: Bioinformatic data mining and in silico modeling indicate a possible interaction of 
propiconazole (Pi) with the AHR. (A) Bioinformatic analysis of microarray gene expression 
data with IPA indicates AHR activation by propiconazole (Pi) in HepaRG cells. The global 
transcriptomic responses of HepaRG cells to 10 µM Pi were analyzed with the help of the 
microarray Agilent Expression Profiling Service. Ingenuity Pathway Analysis (IPA) of the data 
indicates that classic target genes of the nuclear receptor AHR were up (red)- or 
downregulated (green). Duplicates gene identifiers marked with an asterisk (*) indicate that 
multiple identifiers in the dataset file map to a single gene in the Global Molecular Network. 
Colors of the connections represent the predicted relationships (activation (orange), inhibition 
(blue), findings inconsistent with state of downstream molecule (yellow), and effects not 
predicted (gray)). In silico molecular docking analyses of Pi to the AHR ligand binding 
domain are shown as graphic representations of the top-scoring complexes between Pi and 
AHR (B), the reference AHR ligand TCDD and AHR (C), and a superposition of Pi and TCDD 
(D). 
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Figure 2: Propiconazole (Pi) induces AHR-dependent transcription in HepG2 cells. (A) Dose-
dependent induction of a luciferase reporter system driven by a 1.2 kbp fragment of the 
human CYP1A1 promoter. (B) By contrast, no induction is measurable with a similar reporter 
lacking the four functional AHR binding sites (“-CDEF”). (C) Pi also leads to a dose-
dependent induction of the artificial promoter construct consisting of three AHR-responsive 
DRE sequences (“3xDRE”). Induction by the model AHR ligand BbF is shown for 
comparison. Fold induction above solvent control (0.2% DMSO) was calculated. Mean ± SD 
(n=3 independent experiments, each in 3 replicates) is depicted. Statistical significance 
(p<0.05) is indicated by asterisks. 
 
Figure 3: Propiconazole (Pi) is an agonist of human AHR. Induction of CYP1A1 (A) and 
CYP1A2 (B) mRNA levels in HepaRG human hepatoma cells by Pi, as measured by 
quantitative real-time RT-PCR. (C) Pi-dependent induction of CYP1A1 protein level was 
observed by using a mass spectrometry-based approach. (D) Induction of CYP1A1 enzyme 
activity by Pi, as measured by the EROD assay. Fold induction above solvent control (0.2% 
DMSO) was calculated. Mean ± SD (n≥3) is depicted. Statistical significance (p<0.05) is 
indicated by asterisks. No statistical significance was calculated for the data in panel (C), due 
to the fact that these values were not derived from entirely independent experiments. 
 
Figure 4: Propiconazole (Pi) induces AHR target genes and resulting enzyme activities in rat 
livers. Pi leads to an induction of Cyp1a1 (A) and Cyp1a2 (B) mRNA levels in rat livers as 
well as to an induction of the enzyme activities of Cyp1a1 (C) and Cyp1a2 (D). Figures show 
fold induction relative to the respective controls. Mean ± SD (nbiological = 5) is depicted. 
Statistical significance (p<0.05) is indicated by asterisks. 
 
Figure 5: Upregulation of AHR target genes was blocked in AHR KO cells. No induction of 
CYP1A1 (A) and CYP1A2 (B) gene expression was measured in AHR KO cells Additionally 
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no transactivation of Cyp1A1 promoter was measured with 10µM of the AHR inhibitor 
CH223191 (C). In contrast, investigation of CYP1A1 and CYP1A2 in PXR KO (D, E) and 
CAR KO (F, G) cells showed concentration-dependent upregulation, indicating that the latter 
two nuclear receptors are not involved in Cyp1a1/2 induction by propiconazole. Fold 
induction above solvent control (0.2% DMSO) was calculated. Mean ± SD (n≥3) is depicted. 
Statistical significance (p<0.05) is indicated by asterisks. For the receptor experiments, no 
statistical significance was calculated, due to the fact that these values were not derived from 
entirely independent experiments. 
 
Figure 6: Propiconazole (Pi) and the more potent model ligand benzo[b]fluoranthene (BbF) 
have concentration additive effects on human AHR. (A) Pi and BbF both lead to a dose-
dependent induction of the artificial 3xDRE promoter construct. Mixtures of both compounds 
suggest concentration additive combination effects on AHR activation. Furthermore, 
induction of CYP1A1 (B) and CYP1A2 (C) mRNA levels in human HepaRG cells by Pi and 
BbF shows concentration additivity. (D) The results from the EROD assay, which shows the 
induction of CYP1A1 enzyme activity by Pi and BbF, are also in line with concentration 
additivity. Fold induction above solvent control (0.2% DMSO) was calculated. Mean ± SD 
(n=3 independent experiments, each in 3 replicates) is depicted. Statistical significance 
(p<0.05) is indicated by asterisks. 
 
